This biotechnology company develops therapies that inhibit critical cellular pathways responsible for the survival and aggressiveness of solid tumors and hematological cancers. By targeting these mechanisms, the company aims to improve treatment outcomes for cancer patients and enhance their quality of life.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers exhibit resistance to conventional treatments due to the activation of cellular pathways that promote survival and aggressive growth. Current therapies often fail to completely eradicate tumors, leading to relapse and reduced quality of life for patients.
Solution
This biotechnology company is developing targeted therapies designed to inhibit key cellular pathways that drive the survival and aggressiveness of both solid tumors and hematological cancers. By selectively disrupting these mechanisms, the company aims to overcome treatment resistance and improve outcomes for cancer patients. The therapies are designed to specifically target the molecular vulnerabilities of cancer cells, minimizing off-target effects and maximizing efficacy. This approach has the potential to provide more effective and less toxic treatment options for a wide range of cancers.
Target Audience
The primary target audience includes cancer patients, oncologists, and hematologists seeking more effective and targeted treatment options for various types of cancer.
Features
- Inhibition of critical cellular pathways involved in cancer cell survival
- Targeted approach to minimize off-target effects
- Development of therapies for both solid tumors and hematological cancers